Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.20)
# 1,117
Out of 5,138 analysts
175
Total ratings
47.1%
Success rate
1.61%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Downgrades: Neutral | n/a | $12.81 | - | 3 | Nov 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $7.17 | +262.62% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $44.00 | +43.18% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $8.80 | +1,570.45% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $92.32 | -11.18% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $14.07 | -28.93% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $25.58 | +9.46% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.00 | +900.00% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $31.88 | +226.22% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $3.60 | +511.11% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $1.58 | +786.08% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $121.26 | -23.31% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $46.28 | +46.93% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $20.53 | +416.32% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $7.04 | +113.07% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $16.42 | +241.05% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $11.87 | +380.20% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $4.69 | +369.08% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.09 | +713.40% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.71 | +843.40% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $71.12 | -46.57% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $72.60 | -2.20% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $2.45 | +104.08% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $46.31 | -17.94% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.61 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.27 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.78 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.50 | +2,060.00% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $168.57 | - | 2 | Apr 23, 2020 |
Astria Therapeutics
Nov 12, 2025
Downgrades: Neutral
Price Target: n/a
Current: $12.81
Upside: -
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $7.17
Upside: +262.62%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $44.00
Upside: +43.18%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $8.80
Upside: +1,570.45%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $92.32
Upside: -11.18%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $14.07
Upside: -28.93%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $25.58
Upside: +9.46%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.00
Upside: +900.00%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $31.88
Upside: +226.22%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $3.60
Upside: +511.11%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.58
Upside: +786.08%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $121.26
Upside: -23.31%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $46.28
Upside: +46.93%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $20.53
Upside: +416.32%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $7.04
Upside: +113.07%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $16.42
Upside: +241.05%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $11.87
Upside: +380.20%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $4.69
Upside: +369.08%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.09
Upside: +713.40%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.71
Upside: +843.40%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $71.12
Upside: -46.57%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $72.60
Upside: -2.20%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $2.45
Upside: +104.08%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $46.31
Upside: -17.94%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.61
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.27
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.78
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.50
Upside: +2,060.00%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $168.57
Upside: -